Good Distribution Practice or GDP deals with the guidelines for the proper distribution of medicinal products for human use. GDP is a quality warranty system, which includes requirements for purchase, receiving, storage and export of drugs, intended for human consumption.

GDP regulates the division and movement of pharmaceutical products from the premises of the manufacturer of medicinal products, or another central point, to the end user thereof, or to an intermediate point by means of various transport methods, via various storage and/or health establishments.

Legislation

In Europe GDP is based on the Directive of the Board of the European Community 92/25/EEC regarding the wholesale distribution of drugs for human consumption.

In Europe GDP is based on Directive 2001/83/EC, Article 84, replacing of Council Directive 92/25/EEC regarding the wholesale distribution of drugs for human consumption

In China, GDP auditing service was provided by SGS, the world?s leading inspection, verification, testing and certification company. More information via Lawrence.Xu@sgs.com

See also

• GxP
• Good Manufacturing Practice
• Prescription Drug Marketing Act (PDMA) (USA)
• European Medicines Agency (EMEA)
• Packaging and labelling
• Japan Ministry of Health

External links

• Demo applet of an evolutionary algorithm for optimizing goods distribution problems (VRPTW and TSP)
• Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C 63/03)
• Counterfeit Drugs (FDA)
• Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs (FDA)